A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 13,700 shares of ORIC stock, worth $112,203. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,700
Previous 47,000 70.85%
Holding current value
$112,203
Previous $332,000 57.83%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.52 - $11.9 $250,416 - $396,270
-33,300 Reduced 70.85%
13,700 $140,000
Q2 2024

Aug 09, 2024

SELL
$6.63 - $12.93 $423,657 - $826,227
-63,900 Reduced 57.62%
47,000 $332,000
Q1 2024

May 13, 2024

SELL
$8.04 - $16.03 $623,903 - $1.24 Million
-77,600 Reduced 41.17%
110,900 $1.53 Million
Q4 2023

Feb 13, 2024

SELL
$5.41 - $9.43 $1.03 Million - $1.8 Million
-191,300 Reduced 50.37%
188,500 $1.73 Million
Q3 2023

Nov 14, 2023

BUY
$6.05 - $9.28 $218,405 - $335,008
36,100 Added 10.5%
379,800 $2.3 Million
Q2 2023

Aug 11, 2023

SELL
$4.95 - $8.4 $1,980 - $3,360
-400 Reduced 0.12%
343,700 $2.67 Million
Q1 2023

May 12, 2023

BUY
$4.26 - $6.75 $116,298 - $184,275
27,300 Added 8.62%
344,100 $1.96 Million
Q4 2022

Feb 13, 2023

SELL
$2.41 - $5.89 $203,886 - $498,294
-84,600 Reduced 21.08%
316,800 $1.87 Million
Q3 2022

Nov 14, 2022

SELL
$3.15 - $5.24 $146,377 - $243,497
-46,469 Reduced 10.38%
401,400 $1.28 Million
Q2 2022

Aug 12, 2022

BUY
$2.7 - $7.07 $617,676 - $1.62 Million
228,769 Added 104.41%
447,869 $2.01 Million
Q1 2022

May 13, 2022

BUY
$4.54 - $16.1 $875,312 - $3.1 Million
192,800 Added 733.08%
219,100 $1.17 Million
Q4 2021

Feb 11, 2022

BUY
$12.01 - $20.3 $315,863 - $533,890
26,300 New
26,300 $387,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $324M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.